Brooklyn Historical Income Statement

BTX
 Stock
  

USD 0.57  0.02  3.64%   

Historical analysis of Brooklyn Immunotherapeuti income statement accounts such as Cost of Revenue of 9.2 M, Gross Profit of 12.2 M or Interest Expense of 314.2 K can show how well Brooklyn Immunotherapeutics performed in making a profits. Evaluating Brooklyn Immunotherapeuti income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Brooklyn Immunotherapeuti's future profits or losses. Financial Statement Analysis is much more than just reviewing and examining Brooklyn Immunotherapeuti latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Brooklyn Immunotherapeuti is a good buy for the upcoming year.
Continue to Trending Equities.
  
Refresh

Brooklyn Immunotherapeuti Net Income

(125.52 Million)

Share

About Brooklyn Income Statement Analysis

Brooklyn Immunotherapeuti Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Brooklyn Immunotherapeuti shareholders. The income statement also shows Brooklyn investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Brooklyn Immunotherapeuti Income Statement Chart

Brooklyn Immunotherapeutics Income Statement is one of the three primary financial statements used for reporting Brooklyn's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Brooklyn Immunotherapeuti revenue and expense. Brooklyn Immunotherapeuti Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Brooklyn Immunotherapeuti Direct Expenses is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Direct Expenses of 442,750 in 2021. Cost of Revenue is likely to rise to about 9.2 M in 2022, whereas Consolidated Income is likely to drop (125.5 M) in 2022.

Earning Before Interest and Taxes USD

Earning Before Interest and Taxes EBIT in USD; converted by US Dollar Exchange Rate.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Brooklyn Immunotherapeuti financial statement analysis. It represents the amount of money remaining after all of Brooklyn Immunotherapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends Income Statement Impact.

Net Income Common Stock USD

Net Income Common Stock in USD; converted by US Dollar Exchange Rate.

Revenues

Revenues refers to the total amount of money received by Brooklyn Immunotherapeuti for goods sold or services provided during a certain time period. It also includes all of Brooklyn Immunotherapeuti sales as well as any other increase in Brooklyn Immunotherapeutics equity.Revenues are reported on Brooklyn Immunotherapeuti income statement and calculated before any expenses are subtracted. Amount of Revenue recognized from goods sold; services rendered; insurance premiums; or other activities that constitute an earning process. Interest income for financial institutions is reported net of interest expense and provision for credit losses.

Income Tax Expense

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Most accounts from Brooklyn Immunotherapeuti income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Brooklyn Immunotherapeuti current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.Brooklyn Immunotherapeuti Direct Expenses is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Direct Expenses of 442,750 in 2021. Cost of Revenue is likely to rise to about 9.2 M in 2022, whereas Consolidated Income is likely to drop (125.5 M) in 2022.
 2018 2019 2021 2022 (projected)
Interest Expense389 K249 K286.35 K314.17 K
Gross Profit15.27 M12.32 M11.09 M12.18 M

Brooklyn Immunotherapeuti income statement Correlations

Brooklyn Immunotherapeuti Account Relationship Matchups

Brooklyn Immunotherapeuti income statement Accounts

201720182019202020212022 (projected)
Direct Expenses168 K302 K412 K385 K442.75 K541.54 K
Consolidated Income(1.08 M)(259 K)(2.05 M)(26.53 M)(122.31 M)(125.52 M)
Cost of Revenue7.71 M6.75 M8.07 M7.48 M8.61 M9.25 M
Earning Before Interest and Taxes EBIT(513 K)66 K(1.77 M)(26.53 M)(122.3 M)(125.52 M)
Earning Before Interest and Taxes USD(513 K)66 K(1.77 M)(26.53 M)(122.3 M)(125.52 M)
Gross Profit14.6 M14.52 M15.27 M12.32 M11.09 M12.18 M
Interest Expense576 K498 K389 K249 K286.35 K314.17 K
Net Income(1.08 M)(259 K)(2.05 M)(26.53 M)(122.31 M)(125.52 M)
Net Income Common Stock(1.09 M)(275 K)(2.06 M)(26.53 M)(122.32 M)(125.54 M)
Net Income Common Stock USD(1.09 M)(275 K)(2.06 M)(26.53 M)(122.32 M)(125.54 M)
Operating Expenses15.92 M15.06 M14.09 M7.21 M104.98 M113.27 M
Operating Income(1.4 M)203 K(1.77 M)(7.21 M)(104.98 M)(107.75 M)
Revenues22.31 M21.27 M23.34 M19.81 M17.83 M19.16 M
Revenues USD22.31 M21.27 M23.34 M19.81 M17.83 M19.16 M
Selling General and Administrative Expense15.59 M14.46 M13.18 M3.3 M14.72 M14.22 M
Weighted Average Shares1.22 M1.34 M1.44 M17.59 M43.31 M46.72 M
Weighted Average Shares Diluted1.22 M1.34 M1.44 M17.59 M43.31 M46.72 M
Income Tax Expense66 K(64 K)27 K5 K4.5 K4.62 K

Brooklyn Immunotherapeuti Investors Sentiment

The influence of Brooklyn Immunotherapeuti's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brooklyn. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Brooklyn Immunotherapeuti Implied Volatility

    
  35.99  
Brooklyn Immunotherapeuti's implied volatility exposes the market's sentiment of Brooklyn Immunotherapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Brooklyn Immunotherapeuti's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Brooklyn Immunotherapeuti stock will not fluctuate a lot when Brooklyn Immunotherapeuti's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brooklyn Immunotherapeuti in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brooklyn Immunotherapeuti's short interest history, or implied volatility extrapolated from Brooklyn Immunotherapeuti options trading.

Current Sentiment - BTX

Brooklyn Immunotherapeuti Investor Sentiment

Greater number of Macroaxis users are currently bullish on Brooklyn Immunotherapeutics. What is your opinion about investing in Brooklyn Immunotherapeutics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with Brooklyn Immunotherapeuti

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brooklyn Immunotherapeuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brooklyn Immunotherapeuti will appreciate offsetting losses from the drop in the long position's value.

Brooklyn Immunotherapeuti Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Brooklyn Immunotherapeuti could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brooklyn Immunotherapeuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brooklyn Immunotherapeuti - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brooklyn Immunotherapeutics to buy it.
The correlation of Brooklyn Immunotherapeuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brooklyn Immunotherapeuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brooklyn Immunotherapeuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brooklyn Immunotherapeuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.